Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis

Immunology

Volumn 139, Issue 4, 2013, Pages 494-502

  Yin, Hui ^a   Li, Xiangyong ^b   Zhang, Bobin ^a   Liu, Tao ^a   Yuan, Baohong ^a   Ni, Qian ^a   Hu, Shilian ^a   Gu, Hongbiao ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Colitis; Inflammation; Regulatory T cells; Sirolimus; T helper type 17 cells

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; HISTOPATHOLOGY; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE FUNCTION; MALE; MESENTERY LYMPH NODE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH17 CELL; UPREGULATION;

COLITIS; INFLAMMATION; REGULATORY T CELLS; SIROLIMUS; T HELPER TYPE 17 CELLS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CD4 LYMPHOCYTE COUNT; CELLS, CULTURED; COLITIS; COLON; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-17; INTERLEUKIN-6; LYMPH NODES; MALE; MICE; MICE, INBRED BALB C; PHENOTYPE; SIROLIMUS; TH17 CELLS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879805222     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12096     Document Type: Article

References (46)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010; 28:573-621.
2. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3:390-407.
3. Ishihara S, Aziz MM, Yuki T, Kazumori H, Kinoshita Y. Inflammatory bowel disease: review from the aspect of genetics. J Gastroenterol 2009; 44:1097-108.
4. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007; 102:2058-69.
5. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474:298-306.
6. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136:1182-97.
7. Waldner MJ, Neurath MF. Novel cytokine-targeted therapies and intestinal inflammation. Curr Opin Pharmacol 2009; 9:702-7.
8. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 2006; 203:2785-91.
9. + regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010; 30:80-9.
10. Mucida D, Salek-Ardakani S. Regulation of TH17 cells in the mucosal surfaces. J Allergy Clin Immunol 2009; 123:997-1003.
11. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000; 12:1092-9.
12. Graber JJ, Allie SR, Mullen KM et al. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol 2008; 196:124-32.
13. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9:589-93.
14. Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A, Shapiro AM. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009; 58:1302-11.
15. Roncarolo MG, Battaglia M. Regulatory T cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7:585-98.
16. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52:65-70.
17. + Treg in ulcerative colitis. Inflamm Bowel Dis 2007; 13:191-9.
18. Kanai T, Mikami Y, Sujino T, Hisamatsu T, Hibi T. RORγt-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation. Mucosal Immunol 2012; 5:240-7.
19. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006; 212:256-71.
20. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007; 132:2359-70.
21. Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology 2012; 136:115-22.
22. Li Z, Chen L, Niu X, Liu J, Ping M, Li R, Xie X, Guo L. Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE). J Neuroimmunol 2012; 250:9-17.
23. + regulatory T cells. Blood 2011; 118:2342-50.
24. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010; 33:301-11.
25. Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS ONE 2009; 4:e5994.
26. + regulatory T cells cultured with rapamycin. J Immunol 2007; 178:320-9.
27. Levitsky J, Gallon L, Miller J et al. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation 2011; 91:199-206.
28. + Tregs. Nephrol Dial Transplant 2010; 25:710-7.
29. + regulatory T cells. Blood 2005; 105:4743-8.
30. Singh K, Kozyr N, Stempora L, Kirk AD, Larsen CP, Blazar BR, Kean LS. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant 2012; 12:1441-57.
31. Reinecke K, Eminel S, Dierck F et al. The JNK inhibitor XG-102 protects against TNBS-induced colitis. PLoS ONE 2012; 7:e30985.
32. Bai A, Lu N, Guo Y, Liu Z, Chen J, Peng Z. All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. J Leukoc Biol 2009; 86:959-69.
33. Yin H, Li X, Gong Q et al. Heme oxygenase-1 upregulation improves lipopolysaccharide-induced acute lung injury involving suppression of macrophage migration inhibitory factor. Mol Immunol 2010; 47:2443-9.
34. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177:566-73.
35. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86.
36. + T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911.
37. H-17 cell-mediated pathology. Nat Immunol 2007; 8:1390-7.
38. + regulatory T cells. Nat Immunol 2003; 4:330-6.
39. + T helper cells. Cell 2006; 26:1121-33.
40. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol 2012; 12:325-38.
41. + T regulatory cells. Int Immunopharmacol 2007; 7:1819-24.
42. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9:324-37.
43. Delgoffe GM, Pollizzi KN, Waickman AT et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 2011; 12:295-303.
44. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164:4878-82.
45. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-8.
46. Siakavellas SI, Bamias G. Role of the IL-23/IL-17 axis in Crohn's disease. Discov Med 2012; 14:253-62.